Quantinno Capital Management LP Has $35.81 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Quantinno Capital Management LP lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 266.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 396,076 shares of the medical equipment provider’s stock after buying an additional 287,947 shares during the period. Quantinno Capital Management LP’s holdings in Zimmer Biomet were worth $35,813,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. DV Equities LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at approximately $25,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $31,000. Flagship Harbor Advisors LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $32,000. Finally, Headlands Technologies LLC acquired a new position in shares of Zimmer Biomet in the second quarter valued at $37,000. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ZBH. Barclays decreased their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 29th. Citigroup dropped their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. JPMorgan Chase & Co. reduced their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. UBS Group assumed coverage on shares of Zimmer Biomet in a research report on Tuesday. They set a “buy” rating and a $115.00 target price on the stock. Finally, Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $102.00.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Stock Down 2.3%

Shares of NYSE:ZBH opened at $94.90 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm has a market cap of $18.36 billion, a P/E ratio of 24.65, a P/E/G ratio of 2.86 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company’s 50-day moving average price is $88.66 and its two-hundred day moving average price is $89.83.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The company’s revenue was up 9.3% on a year-over-year basis. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.